An antibodies to human il-17

Abstract

An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences. In particular, disclosed does an IL-17 binding molecule comprising both heavy (VH) and light chain (VL) variable domains; said IL-17 binding molecule comprises at least one antigen binding site comprising: a) an immunoglobulin VH domain which comprises in sequence hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence SEQ ID NO:1, said CDR2 having the amino acid sequence SEQ ID NO:2, and said CDR3 having the amino acid sequence SEQ ID NO:3 or direct CDR equivalents thereof, or an immunoglobulin VH domain which comprises in sequence hypervariable regions CDR1-x, CDR2-x and CDR3-x, said CDR1-x having the amino acid sequence SEQ ID NO:11, said CDR2-x having the amino acid sequence SEQ ID NO: 12, and said CDR3- x having the amino acid sequence SEQ ID NO:13 or direct CDR-x equivalents thereof; and b) an immunoglobulin VL domain which comprises in sequence hypervariable regions CDR1', CDR2' and CDR3', said CDR1' having the amino acid sequence SEQ ID NO:4, said CDR2' having the amino acid sequence SEQ ID NO:5, and said CDR3' having the amino acid sequence SEQ ID NO:6 or direct CDR' equivalents thereof, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.